Tenax Therapeutics, Inc. (TENX)

Market Cap	5.10M
Revenue (ttm)	n/a
Net Income (ttm)	-12.59M
Shares Out	29.98M
EPS (ttm)	-0.49
PE Ratio	n/a
Forward PE	0.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	295,344
Open	0.184
Previous Close	0.184
Day's Range	0.170 - 0.190
52-Week Range	0.160 - 1.959
Beta	2.09
Analysts	Buy
Price Target	4.59 (+2,600.0%)
Earnings Date	Nov 14, 2022

About TENX

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hype...

• Industry: Biotechnology
• Founded: 1967
• CEO: John Kelley
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: TENX

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for TENX stock is "Buy." The 12-month stock price forecast is 4.59, which is an increase of 2,600.00% from the latest price.

Price Target

$4.59

(2,600.00% upside)

Analyst Consensus: Buy

Stock Forecasts